Theranostics of uterine leiomyoma: present and future

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.69.95-103

Keywords:

uterine myoma, epigenetics, theranostics, prognosis

Abstract

Research objectives: to develop an algorithm for predicting the growth of uterine fibrodis, taking into account the state of epigenetic regulation.
Materials and methods. The study was conducted on the basis of clinical divisions of the Department of Obstetrics and Gynecology in 2018–2021. 28 patients with uterine fibroids were examined. Expression of miRNA-29b and miRNA-146a in tumor tissue was determined in all women using real-time PCR. Obtained data were analyzed using the statistical program Statistica 10.0 (StatSoft Inc., USA).
Results. The average age of the patients was 39.3 ± 1.0 years. The average number of nodes was 2.7 ± 0.4. The expression levels of microRNA-29b were most frequently determined in the range of 2–7 units and microRNA-146a in the range of 30–67 units in most of the examined tissue samples. The expression of miRNA-29b has the greatest significance for the growth forecast (Wald statistic). According to the logistic regression equation the prognostic factors are patient’s age, estradiol and progesterone level in the I and II phases of the menstrual cycle, diameter of the largest node, expression of miRNA-29b and miRNA-146a.
Conclusions. This study shows that the use of miRNA expression profile as an additional marker in the diagnosis and treatment of uterine fibroids is promising and requires more detailed research. Further study of the correlation of clinical and paraclinical parameters can make it possible to predict the course of uterine fibroids, and therefore to apply an effective personalized treatment plan. Theranostics is a new approach to the diagnosis and treatment of patients, based on the uniqueness of each person in order to choose the optimal treatment strategy against the background of the molecular genetic technologies, in particular to determine epigenetic changes in hyperproliferative diseases. The study of miRNA expression may find its place in the theranostics of uterine fibroids in the future.

Author Biographies

O.S. Salekh, Odesa National Medical University, Odesa

Postgraduate student, Department of Obstetrics and Gynecology

D.M. Zhelezov, City Maternity Hospital No. 5, Odesa

MD, medical director

I.Z. Hladchuk, Odesa National Medical University, Odesa

MD, professor, head of the Obstetrics and Gynecology Department

A.G. Volyanska, Odessa National Medical University, Odesa

MD, professor, Department of Obstetrics and Gynecology

References

  1. Yang, Q., Ciebiera, M., Bariani, M.V., et al. “Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.” Endocr Rev 43.4 (2022): 678–19. DOI: 10.1210/endrev/bnab039. PMID: 34741454; PMCID: PMC9277653.
  2. Stewart, E.A., Nowak, R.A. “Uterine Fibroids: Hiding in Plain Sight.” Physiology (Bethesda) 37.1 (2022): 16–27. DOI: 10.1152/physiol.00013.2021. PMID: 34964688; PMCID: PMC8742728.
  3. American College of Obstetricians and Gynecologists. ACOG guideline. Management of symptomatic uterine leiomyomas. Available from: [https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/management-of-symptomatic-uterine-leiomyomas].
  4. LABOME. MicroRNA Experimental Protocols. Available from: [https://www.labome.com/method/MicroRNA-Experimental-Protocols.html#:~:text=Basic%20 principle%3A%20microRNA%20RT%2DPCR, transcription%20of%20small%20RNA%20U6].
  5. Jeelani, S., Reddy, R.C., Maheswaran, T., et al. “Theranostics: A treasured tailor for tomorrow.” J Pharm Bioallied Sci 6.1 (2014): S6–8. DOI: 10.4103/0975-7406.137249. PMID: 25210387; PMCID: PMC4157283.
  6. Antomonov, M.Y. Mathematical processing and analysis of biomedical data. 2nd ed. Kyiv: Mediinform (2017): 578 р.
  7. Chuang, T.D., Khorram, O. “Regulation of cell cycle regulatory proteins by microRNAs in uterine leiomyoma.” Reproductive Sciences 26.2 (2019): 250–8.
  8. Ciarmela, P., Petraglia, F. “New epigenetic mechanism involved in leiomyoma formation.” Fertil Steril 115.1 (2021): 94–5.
  9. Marsh, E.E., Steinberg, M.L., Parker, J.B., et al. “Decreased expression of microRNA-29 family in leiomyoma contributes to increased major fibrillary collagen production.” Fertil Steril 106.3 (2016): 766–72.
  10. Kolanska, K., Bendifallah, S., Canlorbe, G., et al. “Role of miRNAs in Normal Endometrium and in Endometrial Disorders: Comprehensive Review.” J Clin Med 10.16 (2021): 3457. DOI: 10.3390/jcm10163457. PMID: 34441754; PMCID: PMC8396961.
  11. Chekhun, V.F. “From systemic biology of cancer to the methodology of personalized treatment.” Oncology 14.2 (2012): 84–8.
  12. Goetz, L.H., Schork, N.J. “Personalized medicine: motivation, challenges, and progress.” Fertil Steril 109.6 (2018): 952–63. DOI: 10.1016/j.fertnstert.2018.05.006. PMID: 29935653; PMCID: PMC6366451.
  13. Di Sanzo, M., Cipolloni, L., Borro, M., et al. “Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.” Curr Pharm Biotechnol 18.3 (2017): 194–203. DOI: 10.2174/1389201018666170224105600. PMID: 28240172.
  14. National Academy of Engineering. Engineer Better Medicines. Available from: [http://www.engineeringchallenges.org/challenges/medicines.aspx].
  15. Vicente, A.M., Ballensiefen, W., Jönsson, J.I. “How personalised medicine will transform healthcare by 2030: the ICPerMed vision.” J Transl Med 18.1 (2020): 180. DOI: 10.1186/s12967-020-02316-w
  16. Pulciani, S., Di Lonardo, A., Fagnani, C., Taruscio, D. “P4 Medicine versus Hippocrates.” Ann Ist Super Sanita 53.3 (2017): 185–91. DOI: 10.4415/ANN_17_03_02. PMID: 28956796.
  17. Zannotti, A., Greco, S., Pellegrino, P., et al. “Macrophages and Immune Responses in Uterine Fibroids.” Cells 10.5 (2021): 982. DOI: 10.3390/cells10050982. PMID: 33922329; PMCID: PMC8146588.
  18. Huang, D., Xue, H., Shao, W., et al. “Inhibiting effect of miR-29 on proliferation and migration of uterine leiomyoma via the STAT3 signaling pathway.” Aging (Albany NY) 14.3 (2022): 1307–20. DOI: 10.18632/aging.203873. PMID: 35113040; PMCID: PMC8876902.
  19. Dobson, P. Theranostics: A combination of diagnosis and therapy. Available from: [https://www.ema.europa.eu/en/documents/presentation/presentation-theranosticsnanoparticles-peter-dobson-oxford-university_en.pdf].
  20. Sanli, Y., Garg, I., Kandathil, A., et al. “Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.” AJR Am J Roentgenol 211.2 (2018): 267–77. DOI: 10.2214/AJR.18.19881. PMID: 29975116.
  21. Herrmann, K., Schwaiger, M., Lewis, J.S., et al. “Radiotheranostics: a roadmap for future development.” Lancet Oncol 21.3 (2020): e146-e156. DOI: 10.1016/S1470-2045(19)30821-6. PMID: 32135118; PMCID: PMC7367151.
  22. Navarro, A., Bariani, M.V., Yang, Q., Al-Hendy, A. “Understanding the Impact of Uterine Fibroids on Human Endometrium Function.” Front Cell Dev Biol 9 (2021): 633180. DOI: 10.3389/fcell.2021.633180. PMID: 34113609; PMCID: PMC8186666.
  23. Garello, F., Svenskaya, Y., Parakhonskiy, B., Filippi, M. “Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents.” Pharmaceutics 14.6 (2022): 1132. DOI: 10.3390/pharmaceutics14061132. PMID: 35745705; PMCID: PMC9230665.
  24. Baranov, V.S., Osinovskaya, N.S., Yarmolinskaya, M.I. “Pathogenomics of Uterine Fibroids Development.” Int J Mol Sci 20.24 (2019): 6151. DOI: 10.3390/ijms20246151. PMID: 31817606; PMCID: PMC6940759.
  25. Dumitrescu, R.G. “Early Epigenetic Markers for Precision Medicine.” Methods Mol Biol 1856 (2018): 3–17. DOI: 10.1007/978-1-4939-8751-1_1. PMID: 30178243.

Downloads

Published

2023-09-29

How to Cite

Salekh, O., Zhelezov, D., Hladchuk, I., & Volyanska, A. (2023). Theranostics of uterine leiomyoma: present and future. REPRODUCTIVE ENDOCRINOLOGY, (69), 95–103. https://doi.org/10.18370/2309-4117.2023.69.95-103

Issue

No. 69 (2023)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2023 О.С. Салех, Д.М. Железов, І.З. Гладчук, А.Г. Волянська

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.